| First Author | Zhang D | Year | 2018 |
| Journal | Cancer Res | Volume | 78 |
| Issue | 7 | Pages | 1700-1712 |
| PubMed ID | 29363544 | Mgi Jnum | J:260726 |
| Mgi Id | MGI:6150143 | Doi | 10.1158/0008-5472.CAN-17-1366 |
| Citation | Zhang D, et al. (2018) Tumor-Stroma IL1beta-IRAK4 Feedforward Circuitry Drives Tumor Fibrosis, Chemoresistance, and Poor Prognosis in Pancreatic Cancer. Cancer Res 78(7):1700-1712 |
| abstractText | Targeting the desmoplastic stroma of pancreatic ductal adenocarcinoma (PDAC) holds promise to augment the effect of chemotherapy, but success in the clinic has thus far been limited. Preclinical mouse models suggest that near-depletion of cancer-associated fibroblasts (CAF) carries a risk of accelerating PDAC progression, underscoring the need to concurrently target key signaling mechanisms that drive the malignant attributes of both CAF and PDAC cells. We previously reported that inhibition of IL1 receptor-associated kinase 4 (IRAK4) suppresses NFkappaB activity and promotes response to chemotherapy in PDAC cells. In this study, we report that CAF in PDAC tumors robustly express activated IRAK4 and NFkappaB. IRAK4 expression in CAF promoted NFkappaB activity, drove tumor fibrosis, and supported PDAC cell proliferation, survival, and chemoresistance. Cytokine array analysis of CAF and microarray analysis of PDAC cells identified IL1beta as a key cytokine that activated IRAK4 in CAF. Targeting IRAK4 or IL1beta rendered PDAC tumors less fibrotic and more sensitive to gemcitabine. In clinical specimens of human PDAC, high stromal IL1beta expression associated strongly with poor overall survival. Together, our studies establish a tumor-stroma IL1beta-IRAK4 feedforward signal that can be therapeutically disrupted to increase chemotherapeutic efficacy in PDAC.Significance: Targeting the IL1beta-IRAK4 signaling pathway potentiates the effect of chemotherapy in pancreatic cancer. Cancer Res; 78(7); 1700-12. (c)2018 AACR. |
